| Identification | Back Directory | [Name]
METHOTREXATE HYDRATE | [CAS]
133073-73-1 | [Synonyms]
L-MTX
MTX HYDRATE
Antifolan hydrate
METHOTREXATE, VETEC
METHOTREXATE HYDRATE
L-AMETHOPTERIN HYDRATE
Methotrexate trihydrate
(+)AMETHOPTERINE HYDRATE
(+)-AMETHOPTERIN HYDRATE
METHYLAMINOPTERIN HYDRATE
L-(+)-AMETHOPTERIN HYDRATE
Methotrexate hydrate, >=98%
L(+)-Amethopterin hydrate,99%
4-AMINO-10-METHYLFOLIC ACID HYDRATE
L(+)-AMethopterin hydrate, 99% 100MG
l-4-amino-n10-methylpteroylglutamic acid
L-4-AMINO-N10-METHYLPTEROYL-GLUTAMIC ACID HYDRATE
Methotrexate hydrate Vetec(TM) reagent grade, 98%
N-[4-[[(2,4-diaMino-6-pteridinyl)Methyl]MethylaMino]ben
Methotrexate hydrate
4-AMino-10-Methylfolic acid hydrate
4-Amino-10-methylfolic acid hydrate, Antifolan hydrate, Methotrexate hydrate, Methylaminopterin hydrate, MTX hydrate, L-4-Amino-N10-methylpteroylglutamic acid hydrate
4-Amino-10-methylfolic acid hydrate, L-Amethopterin hydrate, Antifolan hydrate, Methylaminopterin hydrate, MTX hydrate, L-4-Amino-N10-methylpteroylglutamic acid hydrate
Methotrexate hydrate,4-Amino-10-methylfolic acid hydrate, L-4-Amino-N10-methylpteroylglutamic acid hydrate, L-Amethopterin hydrate, Antifolan hydrate, MTX hydrate, Methylaminopterin hydrate
Methotrexate hydrate,4-Amino-10-methylfolic acid hydrate, L-4-Amino-N10-methylpteroylglutamic acid hydrate, L-Amethopterin hydrate, Antifolan hydrate, MTX hydrate, Methotrexate hydrate, Methylaminopte | [EINECS(EC#)]
200-413-8 | [Molecular Formula]
C20H22N8O5 | [MDL Number]
MFCD00150847 | [MOL File]
133073-73-1.mol | [Molecular Weight]
454.44 |
| Chemical Properties | Back Directory | [Appearance]
yellow to orange crystalline powder | [Melting point ]
195 °C | [storage temp. ]
−20°C
| [solubility ]
H2O: insoluble
| [form ]
powder
| [color ]
yellow | [optical activity]
[α]/D +21.0±2.0° | [Stability:]
Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months. | [InChIKey]
FBOZXECLQNJBKD-ZDUSSCGKSA-N |
| Hazard Information | Back Directory | [Chemical Properties]
yellow to orange crystalline powder | [Description]
Methotrexate (MTX) is similar in structure to folic acid (Item No. 20515) and aminopterin (Item No. 21802). It acts by inhibiting the metabolism of folic acid and blocking key enzymes in the synthesis of purines and pyrimidines required for cell proliferation.1,2 MTX is known to induce adenosine release, which mediates many of its anti-inflammatory effects, including the reduction of proinflammatory cytokines.2,3,4 Formulations containing MTX have been used as immunosuppressants, in the treatment of cancer, autoimmune disease, ectopic pregnancy, and for the induction of medical abortions. MTX formulations have been considered the gold standard of disease-modifying antirheumatic drug (DMARD) therapy to treat both the immune-inflammatory and joint destructive processes of rheumatoid arthritis.5 | [Uses]
Potent inhibitor of dihydrofolate reductase and agent for antitumor studies. Use to inhibit dihydrofolate reductase in DHFR-based protein expression systems. Also shows immunosuppressive effects in, e.g., rheumatoid arthritis. | [Definition]
ChEBI: Methotrexate hydrate is a member of folic acids. | [Biochem/physiol Actions]
Methotrexate is an allosteric inhibititor of dihydrofolate reductase (DHFR), the enzyme that catalyzes the conversion of dihydrofolate to tetrahydrofolate. Since tetrahydrolfolate is required for purine and pyrimidine synthesis, methotrexate treatment results in the inhibition of DNA and RNA synthesis. | [storage]
Store at -20°C | [References]
Wessels et al. (2008), Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis; Rheumatology (Oxford), 47 249
Allegra et al. (1987), Evidence for direct inhibition of de novo purine synthesis in human MCF-7 breast cells as a principal mode of metabolic inhibition by methotrexate; Biol. Chem., 262 13520
Chu et al. (1990), Mechanism of thymidylate synthase inhibition by methotrexate in human neoplastic cell lines and normal human myeloid progenitor cells; Biol. Chem., 265 8470
Gerards et al. (2003), Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis; Rheumatology (Oxford), 42 1189
Friedman and Cronstein (2019), Methotrexate mechanism in treatment of rheumatoid arthritis; Joint Bone Spine, 86 301
Smolen and Steiner (2003), Therapeutic strategies for rheumatoid arthritis; Rev. Drug Discov., 2 473 |
|
|